Efexor XR

Efexor XR

venlafaxine

Manufacturer:

Viatris

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Venlafaxine HCl
Indications/Uses
Depression including depression w/ associated anxiety. Generalized anxiety disorder (GAD) including long-term treatment. Social anxiety disorder (SAD or social phobia), panic disorder including prevention of relapse. Prevention of relapse & recurrence of depression.
Dosage/Direction for Use
Major depressive disorder Initially 75 mg once daily, may be increased to max: 225 mg daily. Dose can be titrated up to 225 mg daily in moderate depression & 375 mg daily in severe depression. GAD Initially 75 mg once daily, may be increased up to max: 225 mg daily. SAD Initially 75 mg once daily. Panic disorder Initially 37.5 mg daily for 7 days, then increased to 75 mg daily. May be further increased up to max: 225 mg daily.
Administration
Should be taken with food: Take at the same time each day. Swallow whole, do not chew/crush/divide/dissolve. Cap may be carefully opened & entire contents sprinkled on a spoonful of applesauce. Swallow drug/food mixt w/o chewing immediately after prep & followed w/ glass of water.
Contraindications
Hypersensitivity. Concomitant use or w/in at least 14 days after discontinuation of MAOIs. Discontinue use for at least 7 days before initiating MAOI.
Special Precautions
Monitor patients for suicide/suicidal thoughts or clinical worsening. Increased risk of bone fractures. History of MI or unstable heart disease, convulsions, bipolar disorder or aggression. NMS-like reactions; sexual dysfunction; hyponatermia; risk factors for QTc prolongation; patients predisposed to bleeding. Closely monitor patients w/ raised IOP or at risk for acute narrow-angle glaucoma. Abuse & dependence. Monitor BP, control preexisting HTN in BP or heart rate compromised patients. Measure serum cholesterol in long-term use. Avoid abrupt discontinuation. Not recommended in concomitant use w/ serotonin precursors eg, tryptophan supplements; wt loss agents. May affect ability to drive & use machines. Renal or hepatic impairment. Pregnancy & lactation. Childn & adolescents <18 yr. Elderly.
Adverse Reactions
Insomnia; headache, dizziness, sedation; nausea, dry mouth, constipation; hyperhidrosis. Decreased appetite; abnormal dreams, nervousness, decreased libido, agitation, anorgasmia; akathisia, tremor, paraesthesia, dysgeusia; visual impairment, accommodation disorder, mydriasis; tinnitus; tachycardia, palpitations; HTN, hot flush; dyspnoea, yawning; diarrhoea, vomiting; rash, pruritus, night sweats; hypertonia; urinary hesitation & retention, pollakiuria; erectile dysfunction, ejaculation disorder; fatigue, asthenia, chills; decreased/increased wt.
Drug Interactions
Severe ARs w/ MAOIs. Serotonin syndrome w/ other serotonergic agents eg, triptans, SSRIs, other SNRIs, amphetamines, lithium, sibutramine, fentanyl & its analogues, tramadol, dextromethorphan, tapentadol, meperidine, methadone, pentazocine, St. John's wort; drugs impairing serotonin metabolism eg, linezolid & methylene blue or serotonin precursors eg, tryptophan supplements. Risk of QTc prolongation &/or ventricular arrhythmias w/ some antipsychotics & antibiotics. Decreased AUC & Cmax of indinavir. Increased AUC & Cmax of haloperidol. Increased AUC, Cmax & Cmin of desipramine. Increased plasma conc w/ ketoconazole, metoprolol. Increased AUC of risperidone. Reduced metabolism w/ CYP2D6 inhibitors. Increased levels w/ CYP3A4 inhibitors. False +ve urine immunoassay screening tests for PCP & amphetamine. Concomitant use w/ CNS-active drugs; ethanol.
MIMS Class
Antidepressants
ATC Classification
N06AX16 - venlafaxine ; Belongs to the class of other antidepressants.
Presentation/Packing
Form
Efexor XR XR cap 150 mg
Packing/Price
28's
Form
Efexor XR XR cap 37.5 mg
Packing/Price
7's
Form
Efexor XR XR cap 75 mg
Packing/Price
28's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in